Helix BioMedix Inc (HXBM) fair value: what the stock is really worth
As of Sep 24, 2026: fair value of Helix BioMedix Inc $6.84, price $5.00, upside +36.8%, quality 53 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Helix BioMedix Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $1.00 – $26.00 · fair‑value band $4.51 – $8.54 · the $5.00 price screens below the $6.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 23, 2026.
Follow Helix BioMedix in your weekly email
Every Wednesday you see whether Helix BioMedix is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies.
Show more
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Stock analysis
Helix BioMedix Inc (HXBM) currently trades at $5.00, while our model-based Fair Value estimate is $6.84, implying the stock looks roughly 26.9% undervalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: $4.51 (bear) to $8.54 (bull), the price of $5.00 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 53/100 (solid quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Helix BioMedix Inc reported revenue of $807K in FY2025 versus $2.4M in FY2021, a compound −23.6%/yr. Reported net income was −$552K in FY2025.
Key figures
Market cap $402K · P/S ratio 0.19 · EPS (TTM) $−0.9000 · Net margin −68.3% · Return on equity −123% · Return on assets (EBIT) −34.2% · Operating margin −160% · Revenue (TTM) $2.1M.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 400% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at 37%, HXBM screens cheaper than that median.
Fair Value models
Bear $4.51Fair Value $6.84Bull $8.54
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−22.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−15.2%
Start year 2020 (pandemic)
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.2%
’09
’10
’11
’12
’13
’14
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−67.0% (2020) → −73.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 5/9 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Above median
Fair Value upside+37% · Top 25%
Profitability
Return on assets−59% · Bottom 25%
Net margin (TTM)−125% · Bottom 25%
Operating margin (TTM)−160% · Bottom 25%
Growth and dividend
Revenue growth19% · Above median
Balance sheet
Debt / equity0.29× · Highest 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Helix BioMedix Inc (HXBM) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $6.84 versus a price of $5.00, about +37% upside (undervalued).
What is the fair value of HXBM?
Our model-based fair value for Helix BioMedix Inc is $6.84 (as of Sep 23, 2026), built from audited fundamentals. The current price: $5.00.
What is the quality score of HXBM?
Helix BioMedix Inc has a Quality Score of 53/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Helix BioMedix Inc (HXBM)?
Our model-based price target is the fair value of $6.84 (as of Sep 23, 2026) from 1 valuation models. Cautious scenario $4.51, optimistic scenario $8.54. It is a calculation from audited fundamentals, not an analyst target.
What is the Helix BioMedix Inc stock forecast for 2026?
Our models put fair value at $6.84, about +37% upside versus a price of $5.00 (undervalued). Cautious scenario $4.51, optimistic scenario $8.54. The calculation is refreshed regularly with new filings.
What is the revenue of Helix BioMedix Inc (HXBM)?
Helix BioMedix Inc reported trailing-twelve-month revenue of about $2.1M (latest available figure, as of Sep 23, 2026).
What is the intrinsic value of Helix BioMedix Inc (HXBM)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Helix BioMedix Inc it is $6.84 per share (as of Sep 23, 2026), against a price of $5.00. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Helix BioMedix Inc stock overvalued or undervalued in 2026?
As of Sep 23, 2026, HXBM trades below its calculated fair value: price $5.00, fair value $6.84, a gap of about +37% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of HXBM?
No. The price is what the market pays today ($5.00); the fair value is what the company's own numbers justify ($6.84). For Helix BioMedix Inc the two are $1.84 per share apart. That gap is exactly why we show both numbers side by side.
How much is Helix BioMedix Inc worth?
The market values Helix BioMedix Inc at about $402K (market capitalisation, as of Sep 23, 2026). Per share that is $5.00; our models calculate a fair value of $6.84 per share.
What do the bullish and bearish scenarios say about HXBM?
Our models span a range for Helix BioMedix Inc: cautious scenario $4.51, base $6.84, optimistic $8.54 per share (as of Sep 23, 2026, price $5.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Helix BioMedix Inc (HXBM)?
Balance-sheet figures for Helix BioMedix Inc (as of Sep 23, 2026): return on equity −122.5%, debt of 0.29 per unit of equity. They feed the Quality Score of 53/100, which measures business quality independently of the share price.
How far is HXBM from its 52-week high?
Helix BioMedix Inc trades at $5.00, about 23% below its 52-week high of $6.50 and 400% above the low of $1.00 (as of Sep 24, 2026). Distance from the high says nothing about value: that is what the fair value of $6.84 is for.
Which stocks are comparable to Helix BioMedix Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Helix BioMedix Inc stock attractive at the current price?
The data as of Sep 23, 2026: price $5.00, calculated fair value $6.84 (+37%), Quality Score 53/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of HXBM calculated?
We run Helix BioMedix Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $6.84, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Helix BioMedix Inc currently trades 37 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Helix BioMedix Inc (HXBM)?
The closing price on Sep 24, 2026 was $5.00. Our model-based fair value is $6.84, about +37% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Helix BioMedix Inc right now?
The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (53/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range ($4.51 to $8.54) leaves room in how you read the outcome.
Key figures of Helix BioMedix Inc
How large is the market capitalisation of Helix BioMedix Inc (HXBM)?
The market capitalisation of Helix BioMedix Inc is $402K. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Helix BioMedix Inc (HXBM)?
The price-to-sales ratio of Helix BioMedix Inc is 0.19 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Helix BioMedix Inc (HXBM)?
Earnings per share at Helix BioMedix Inc are $−0.9000. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Helix BioMedix Inc (HXBM)?
The net margin of Helix BioMedix Inc is −68.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Helix BioMedix Inc (HXBM)?
The return on equity (ROE) of Helix BioMedix Inc is −123% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Helix BioMedix Inc (HXBM)?
On an EBIT basis the return on assets of Helix BioMedix Inc is −34.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Helix BioMedix Inc (HXBM)?
The operating margin of Helix BioMedix Inc is −160% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Helix BioMedix Inc (HXBM)?
Revenue at Helix BioMedix Inc is growing +18.8% versus a year earlier (3y avg −22.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Helix BioMedix Inc (HXBM) generate?
The free cash flow of Helix BioMedix Inc is −$601K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Helix BioMedix Inc (HXBM) hold?
Helix BioMedix Inc holds more cash than debt, $1.3M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Helix BioMedix Inc in the live analysis
One click puts Helix BioMedix Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 23, 2026